# Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer

> **NCT00303628** · PHASE3 · TERMINATED · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 355 (actual)

## Conditions studied

- Adenocarcinoma of the Rectum
- Stage II Rectal Cancer
- Stage III Rectal Cancer

## Interventions

- **DRUG:** oxaliplatin
- **DRUG:** fluorouracil
- **DRUG:** leucovorin calcium
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00303628
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05-11
- **Primary completion:** 2015-04
- **Final completion:** 2019-02-11
- **Target enrollment:** 355 (ACTUAL)
- **Why stopped:** The study was terminated before reaching its accrual goal due to slow accrual.
- **Last updated:** 2023-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00303628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00303628, "Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00303628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*